ASCO 2025 | The evolving role of immunotherapies and vaccines in cervical cancer
Ritu Salani, MD, MBA, University of California Los Angeles, Los Angeles, CA, comments on the novel treatment opportunities in cervical cancer such as antibody-drug conjugate (ADCs), vaccines, and immunotherapy combinations. These therapies have the potential to be combined safely with existing treatments to improve patient outcomes and move earlier into lines of therapy, with the ultimate goal of curing patients in the primary setting. This interview took place during the 2025 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
I think yes, there’s lots of opportunities in cervical cancer. You know, we’re still understanding what cervical cancer was a little late to the kind of, I guess, genetic landscape game. We’re understanding what molecular targets there may be. But yes, there are a lot of other opportunities. And it’s not just about ADCs. There’s also like vaccine targets or, you know, other immunotherapy combinations...
I think yes, there’s lots of opportunities in cervical cancer. You know, we’re still understanding what cervical cancer was a little late to the kind of, I guess, genetic landscape game. We’re understanding what molecular targets there may be. But yes, there are a lot of other opportunities. And it’s not just about ADCs. There’s also like vaccine targets or, you know, other immunotherapy combinations. So I think the opportunities are limitless in cervical cancer. And I think it’s a really exciting time. And to your second question, which I think is really provocative, yeah, I do hope that these therapies provide better care and can be combined safely with chemotherapy, immunotherapy, even radiation and move earlier into lines of therapy. Our goal is to cure patients, not just to help them live longer, but to really cure them from this disease. And the best opportunity to do that is in the primary setting.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
